Yesterday, Dec. 22, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $102.00 to $44,180,000.00.

Highlighted Stocks Traded by Insiders:

Main Street Capital (MAIN) - FREE Research Report

Solcher Stephen B, who is Director at Main Street Capital, bought 8 shares at $30.15 on Dec. 22, 2015. Following this transaction, the Director owned 2,305 shares meaning that the stake was boosted by 0.34% with the 8-share transaction.

Canon Joseph E, who is Director at Main Street Capital, bought 215 shares at $30.15 on Dec. 22, 2015. Following this transaction, the Director owned 46,545 shares meaning that the stake was boosted by 0.46% with the 215-share transaction.

Hyzak Dwayne L., who is President, COO, SMD at Main Street Capital, bought 346 shares at $30.15 on Dec. 22, 2015. Following this transaction, the President, COO, SMD owned 288,983 shares meaning that the stake was boosted by 0.12% with the 346-share transaction.

Stout Rodger A., who is Evp at Main Street Capital, bought 111 shares at $30.15 on Dec. 22, 2015. Following this transaction, the Evp owned 150,299 shares meaning that the stake was boosted by 0.07% with the 111-share transaction.

Appling Michael JR, who is Director at Main Street Capital, bought 588 shares at $30.15 on Dec. 22, 2015. Following this transaction, the Director owned 100,164 shares meaning that the stake was boosted by 0.59% with the 588-share transaction.

Smith Brent D., who is CFO, Treasurer at Main Street Capital, bought 38 shares at $30.15 on Dec. 22, 2015. Following this transaction, the CFO, Treasurer owned 12,665 shares meaning that the stake was boosted by 0.3% with the 38-share transaction.

Griffin Jon Kevin, who is Director at Main Street Capital, bought 90 shares at $30.15 on Dec. 22, 2015. Following this transaction, the Director owned 17,961 shares meaning that the stake was boosted by 0.5% with the 90-share transaction.

Martin Shannon, who is VP, Chief Accounting Officer at Main Street Capital, bought 38 shares at $30.15 on Dec. 22, 2015. Following this transaction, the VP, Chief Accounting Officer owned 23,739 shares meaning that the stake was boosted by 0.16% with the 38-share transaction.

The shares most recently traded at $30.31, up $0.16, or 0.53% since the insider transaction. Historical insider transactions for Main Street Capital go as follows:

  • 4-Week # shares bought: 1,000
  • 12-Week # shares bought: 1,000
  • 24-Week # shares bought: 5,000

The average volume for Main Street Capital has been 316,900 shares per day over the past 30 days. Main Street Capital has a market cap of $1.4 billion and is part of the financial sector and financial services industry. Shares are up 1.61% year-to-date as of the close of trading on Tuesday.

Main Street Capital Corporation is a business development company specializing in long- term equity and debt investments in small and lower middle market companies. The stock currently has a dividend yield of 7.49%. The company has a P/E ratio of 13.1. Currently, there are 5 analysts who rate Main Street Capital a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MAIN - FREE

TheStreet Quant Ratings rates Main Street Capital as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Main Street Capital Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Tejon Ranch (TRC) - FREE Research Report

Atkinson Dennis, who is Sr. Vice President at Tejon Ranch, sold 20,000 shares at $19.46 on Dec. 22, 2015. Following this transaction, the Sr. Vice President owned 19,251 shares meaning that the stake was reduced by 50.95% with the 20,000-share transaction.

The shares most recently traded at $19.58, up $0.11, or 0.59% since the insider transaction. Historical insider transactions for Tejon Ranch go as follows:

  • 4-Week # shares bought: 53,773
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 79,501
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 133,749
  • 24-Week # shares sold: 1,000

The average volume for Tejon Ranch has been 38,100 shares per day over the past 30 days. Tejon Ranch has a market cap of $402.9 million and is part of the financial sector and real estate industry. Shares are down 33.4% year-to-date as of the close of trading on Tuesday.

Tejon Ranch Co. operates as a diversified real estate development and agribusiness company. The company operates through four segments: Commercial/Industrial Real Estate Development, Resort/Residential Real Estate Development, Mineral Resources, and Farming. The company has a P/E ratio of 129.9. Currently, there are no analysts who rate Tejon Ranch a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TRC - FREE

TheStreet Quant Ratings rates Tejon Ranch as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, unimpressive growth in net income, poor profit margins and weak operating cash flow. Get the full Tejon Ranch Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biocryst Pharmaceuticals (BCRX) - FREE Research Report

Staab Thomas R Ii, who is Senior Vice President and CFO at Biocryst Pharmaceuticals, sold 3,052 shares at $10.86 on Dec. 22, 2015. Following this transaction, the Senior Vice President and CFO owned 136,592 shares meaning that the stake was reduced by 2.19% with the 3,052-share transaction.

The shares most recently traded at $10.66, down $0.20, or 1.88% since the insider transaction. Historical insider transactions for Biocryst Pharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 6,500

The average volume for Biocryst Pharmaceuticals has been 923,800 shares per day over the past 30 days. Biocryst Pharmaceuticals has a market cap of $798.6 million and is part of the health care sector and drugs industry. Shares are down 13.24% year-to-date as of the close of trading on Tuesday.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Currently, there are 5 analysts who rate Biocryst Pharmaceuticals a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCRX - FREE

TheStreet Quant Ratings rates Biocryst Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Biocryst Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.